Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?

Cardinal Health (CAH) has significantly outperformed its medical sector peers year-to-date, posting a 27.6% return compared to the sector's average decline of 1.3%. This strong performance is supported by a Zacks Rank #2 (Buy) and a 4.3% increase in its full-year earnings consensus estimate over the past 90 days, indicating improving analyst sentiment and a positive earnings outlook. Investors are advised to monitor CAH, along with Adaptive Biotechnologies (ADPT), which also demonstrated substantial year-to-date gains of 110.3%.

Analysis

Cardinal Health (CAH) has demonstrated significant market outperformance year-to-date, delivering a 27.6% return that starkly contrasts with the broader Medical sector's average decline of 1.3% and its direct Medical - Dental Supplies industry's 1.5% loss. This performance is not solely based on price momentum but is supported by strengthening fundamentals, as indicated by a 4.3% upward revision in the Zacks Consensus Estimate for its full-year earnings over the past 90 days. This positive shift in analyst sentiment has earned the company a Zacks Rank of #2 (Buy), a model which historically identifies stocks poised to outperform over a one-to-three-month horizon. While the broader Medical sector holds a middling rank (#7 out of 16), CAH's ability to excel within a poorly performing industry (#156) points to company-specific drivers. The article draws a parallel with Adaptive Biotechnologies (ADPT), another #2 (Buy) ranked stock, which has seen even more substantial momentum with a 110.3% YTD return and a 17.6% increase in its EPS consensus, highlighting a theme of identifying individual winners despite mixed sector-level performance.

Key Decisions for Investors

• Given the combination of strong price momentum, positive earnings estimate revisions, and a Zacks #2 (Buy) rating, investors with an appetite for the medical sector may consider CAH a fundamentally strong candidate.
• Investors should closely monitor for continued upward revisions in CAH's earnings estimates, as this is the primary quantitative signal underpinning the current bullish thesis presented.
• Note that CAH's strength is company-specific, as it is outpacing a lagging industry, which warrants attention to its fundamental drivers versus broad industry tailwinds.
• Consider keeping Adaptive Biotechnologies (ADPT) on a watchlist, as it is highlighted as another high-momentum stock in the medical space with similar positive signals.